News
September 7, 2022
Investor
Summary of Consolidated Financial Results for the Year Ended July 31, 2022 (Based on Japanese GAAP) 
June 6, 2022
Investor
Company Research And Analysis Report（FISCO）
June 6, 2022
Investor
Summary of Consolidated Financial Results for the Nine Months Ended April 30, 2022 (Based on Japanese GAAP)
April 8, 2022
Media
NHK WORLD-JAPAN「Reusing Eggshells to Create New Materials」
March 10, 2022
Investor
Summary of Consolidated Financial Results for the Six Months Ended January 31, 2022 (Based on Japanese GAAP)
January 21, 2022
Research and Development
Towards the Expansion of Cognitive Health Market in North America.Health Canada Recognizes Functional Properties of PharmaGABA
November 15, 2021
Investor
Company Research And Analysis Report（FISCO）
September 28, 2021
Investor
Notice of the 24th Annual General Meeting of Shareholders
March 15, 2021
Investor
Pharma Foods Announces Conclusion of Capital and Business Alliance with Sanyo Chemical
January 26, 2021
Investor
PFI Enters into Exclusive Licensing Agreement with Mitsubishi Tanabe Pharma Corporation for a New Therapeutic Antibody to treat Autoimmune Diseases
June 6, 2022
Investor
Company Research And Analysis Report（FISCO）
June 6, 2022
Investor
Summary of Consolidated Financial Results for the Nine Months Ended April 30, 2022 (Based on Japanese GAAP)
April 8, 2022
Media
NHK WORLD-JAPAN「Reusing Eggshells to Create New Materials」
March 10, 2022
Investor
Summary of Consolidated Financial Results for the Six Months Ended January 31, 2022 (Based on Japanese GAAP)
January 21, 2022
Research and Development
Towards the Expansion of Cognitive Health Market in North America.Health Canada Recognizes Functional Properties of PharmaGABA
November 15, 2021
Investor
Company Research And Analysis Report（FISCO）
September 28, 2021
Investor
Notice of the 24th Annual General Meeting of Shareholders
March 15, 2021
Investor
Pharma Foods Announces Conclusion of Capital and Business Alliance with Sanyo Chemical
January 26, 2021
Investor
PFI Enters into Exclusive Licensing Agreement with Mitsubishi Tanabe Pharma Corporation for a New Therapeutic Antibody to treat Autoimmune Diseases